(Damistimagene matitucel + enistimagene setitucel) is under clinical development by Chinook Therapeutics and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According to GlobalData, Phase II drugs for Metastatic Adenocarcinoma of The Pancreas have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Damistimagene matitucel + enistimagene setitucel)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Damistimagene matitucel + enistimagene setitucel) overview

Damistimagene matitucel in a fixed-dose combination with enistimagene setitucel (GVAX pancreatic cancer vaccine) is under development for the treatment of metastatic pancreatic adenocarcinoma. It is administered intradermally. The vaccine candidate comprises of two allogeneic irradiated pancreatic tumor cell lines, Panc 10.05 and Panc 6.03, which are genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF). The vaccine candidate is developed based on GVAX platform technology.

Chinook Therapeutics overview

Chinook Therapeutics, Inc (Chinook)., formerly Aduro BioTech Inc is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sting pathway activators; and B-select monoclonal antibodies to create immunotherapies for the treatment of cancers, infectious and autoimmune diseases. Its products are under development and are intended for the treatment of variety of cancers, including metastatic colorectal, multiple myeloma cancers, as well as other solid tumors and lymphomas. The company collaborates with various pharmaceutical companies to expand its products, and technology platforms. It has an operational presence in The Netherlands. Chinook is headquartered in Berkeley, California, the US.

For a complete picture of (Damistimagene matitucel + enistimagene setitucel)’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.